AMPK–SQSTM1 Feedback Enhances Antioxidant Defense in Metabolic Stress

Study Background and Research Question

The tumor microenvironment is characterized by chronic inflammation, nutrient depletion, and high levels of reactive oxygen species (ROS), creating persistent metabolic and oxidative stress that challenges cancer cell survival. Key signaling pathways, such as the STK11/LKB1-AMPK axis and the KEAP1-NFE2L2/NRF2 pathway, are central to the cellular adaptation to these hostile conditions. Notably, co-occurring mutations in KEAP1 and STK11/LKB1 are observed in certain non-small cell lung cancers (NSCLC), but the mechanistic basis for their cooperation in metabolic adaptation has remained unclear. The recent AUTOPHAGY 2024 study addressed the critical question: how do energy and redox-sensing pathways crosstalk at the molecular level to optimize antioxidant defense under metabolic stress?

Key Innovation from the Reference Study

The central innovation of this work is the discovery of a double-positive feedback loop between AMPK (AMP-activated protein kinase) and SQSTM1/p62, which orchestrates the dual activation of AMPK and the transcription factor NFE2L2/NRF2. This feedback mechanism not only enhances antioxidant defenses but also clarifies why co-mutations in STK11/LKB1 and KEAP1 synergize in tumor cells during metabolic stress. The study elucidates how metabolic stress-induced changes in SQSTM1/p62 expression and phosphorylation facilitate this signaling crosstalk, integrating lysosomal, metabolic, and oxidative stress responses.

Methods and Experimental Design Insights

The investigators used a combination of biochemical, genetic, and imaging approaches in both mouse embryonic fibroblasts (MEFs) and NSCLC cell models. Key methods included:

• Induction of metabolic stress via glucose deprivation or pharmacological inhibitors to simulate the nutrient-poor tumor microenvironment.
• Western blotting and immunoprecipitation to assess the expression, phosphorylation, and complex formation of key proteins (AMPK, SQSTM1/p62, KEAP1, NFE2L2/NRF2).
• Loss- and gain-of-function experiments (e.g., gene knockdowns and overexpression) to dissect the causal relationships between pathway components.
• Use of pharmacological modulators, including MAP3K7/TAK1 inhibitors, to probe the upstream regulation of SQSTM1 phosphorylation.
• Functional readouts such as antioxidant capacity, ROS levels, and tumor cell growth under metabolic stress conditions.

Core Findings and Why They Matter

The study's core findings can be summarized as follows:

• Metabolic stress increases SQSTM1/p62 expression and phosphorylation: Both the abundance and phosphorylation state of SQSTM1/p62 were elevated in response to nutrient deprivation, with phosphorylation at S24 and S226 being critical for downstream effects.
• AMPK and NFE2L2/NRF2 are dually activated: Elevated SQSTM1/p62 promotes the degradation of KEAP1 (the cytosolic inhibitor of NRF2), thereby releasing NFE2L2/NRF2 for nuclear translocation and antioxidant gene expression. Simultaneously, SQSTM1 facilitates the assembly of the AXIN-STK11-AMPK complex on lysosomal membranes, activating AMPK.
• Positive feedback between AMPK and SQSTM1: Not only does SQSTM1 activate AMPK, but AMPK activity is also required for metabolic stress-induced SQSTM1 expression and phosphorylation, forming a double-positive feedback loop.
• MAP3K7/TAK1 as a key upstream regulator: Phosphorylation of SQSTM1 at S24 and S226 was shown to depend on MAP3K7/TAK1 activity, which is activated by ROS and lysosomal Ca²⁺ fluxes under low glucose conditions.
• Functional consequences: This dual activation mechanism synergistically enhances cellular antioxidant defense, supporting tumor cell survival and growth in metabolically stressed environments. Importantly, these effects were reversed by the addition of lactic acid, which restores lysosomal acidity.

Collectively, these findings reveal a tightly coupled regulatory axis that links metabolic sensing, autophagy, and antioxidant defense—helping to rationalize the frequent co-mutation of KEAP1 and STK11/LKB1 in NSCLC and providing new molecular entry points for therapeutic intervention.

Comparison with Existing Internal Articles

Several recent internal resources contextualize and extend the findings of this study:

• The article "AMPK–SQSTM1 Double Feedback Promotes Antioxidant Defense in Stress" provides a focused summary of how the AMPK–SQSTM1 loop enables tumor cells to adapt to metabolic and oxidative stress, highlighting the translational relevance for inflammation and cancer research.
• "AMPK–SQSTM1 Feedback Enhances Antioxidant Defense in Cancer Stress" further explores these mechanisms, emphasizing the importance of feedback-driven adaptation and the potential for targeting this axis in metabolic disease and oncology.
• For researchers interested in pathway dissection, "(5Z)-7-Oxozeaenol: Workflow Optimization for TAK1 Inhibition" and "(5Z)-7-Oxozeaenol: Advanced TAK1 Inhibitor Workflows in Inflammation" provide detailed protocols for using selective TAK1 inhibitors—including (5Z)-7-Oxozeaenol—to probe the contributions of MAP3K7/TAK1 in these feedback circuits.

These resources collectively support the translation of mechanistic insights from the reference study into actionable experimental workflows, particularly for dissecting the regulatory roles of TAK1 and SQSTM1/p62 in metabolic stress settings.

Limitations and Transferability

Despite its strengths, the study has several limitations. Most mechanistic work was performed in cell lines and murine models, which may not fully capture the complexity of human tumors or the influence of the broader tumor microenvironment. The feedback circuitry described could differ in other cancer types or under distinct metabolic pressures. Additionally, while pharmacological inhibition of TAK1 (e.g., with (5Z)-7-Oxozeaenol) confirmed the involvement of this kinase in SQSTM1 phosphorylation, off-target effects or compensatory signaling could complicate interpretation in vivo. Thus, while the feedback model is robustly supported in the tested systems, further validation in patient-derived samples and diverse tumor contexts remains necessary.

Protocol Parameters

• Glucose deprivation: Typically 16–24 hours in low-glucose (<1 mM) medium to induce metabolic stress and activate AMPK–SQSTM1 signaling.
• (5Z)-7-Oxozeaenol treatment: For selective TAK1 inhibition in cell signaling assays, use at 500 nM for approximately 17.5 hours in culture, as recommended by the product information.
• SQSTM1 phosphorylation analysis: Assess S24/S226 phosphorylation via immunoblotting after TAK1 inhibition to confirm pathway involvement.
• Lysosomal pH modulation: Addition of lactic acid (10–20 mM) for 2–4 hours can be used to re-acidify lysosomes and test effects on feedback disruption, following literature approaches.
• Antioxidant response assessment: Measure ROS levels and NFE2L2/NRF2 target gene expression as downstream readouts of pathway activation.

These parameters are based on reference data and internal workflow recommendations; optimization for specific cell lines or models may be required.

Research Support Resources

Researchers aiming to dissect the role of TAK1 in the AMPK–SQSTM1 feedback loop or related inflammation pathways can utilize (5Z)-7-Oxozeaenol (SKU B7443) as a highly selective TAK1 inhibitor. This compound enables precise interrogation of TAK1-dependent SQSTM1 phosphorylation and downstream signaling, as highlighted in both the reference study and internal protocol articles. For reproducible workflows and up-to-date recommendations, APExBIO provides detailed usage information and guidance on compound handling.